Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dhimant Balar

Sports Medicine Freehold, NJ Doctor of Osteopathy

NPI 1417001587 CMS profile 18991

901 W Main St Ste 267, Freehold, NJ 07728

Open in the dashboard

General payments

$6,750

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dhimant Balar of Freehold, NJ is reported in the CMS Open Payments database as having received $6,750 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $140 5
2024 General $119 4
2023 General $1,150 14
2022 General $2,805 36
2021 General $2,138 25
2020 General $172 10
2019 General $228 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhimant Balar
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Dhimant Balar were reported at $140. Among 132 Sports Medicine profiles paid that year, the median was $99 and the middle half received between $33 and $256.

Show as a table
Year Dhimant Balar Sports Medicine median Middle half National median
2019 $228 $131 $46–$324 $163
2020 $172 $96 $34–$276 $114
2021 $2,138 $120 $33–$421 $132
2022 $2,805 $107 $31–$274 $149
2023 $1,150 $63 $25–$180 $160
2024 $119 $104 $28–$282 $164
2025 $140 $99 $33–$256 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SI-BONE, Inc. $3,687 43 payments
  2. Electronic Waveform Lab, Inc. $904 6 payments
  3. Stryker Corporation $548 7 payments
  4. Nevro Corp. $348 4 payments
  5. DePuy Synthes Sales Inc. $270 12 payments
  6. Horizon Therapeutics plc $208 10 payments
  7. Pfizer Inc. $151 5 payments
  8. Zimmer Biomet Holdings, Inc. $127 3 payments
  9. Intrinsic Therapeutics $115 1 payment
  10. Boston Scientific Corporation $77 1 payment
  11. Other $315 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,046 104 payments
  2. Travel and Lodging $403 1 payment
  3. Consulting Fee $301 2 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT $2,066 22 payments
  2. VITOSS $241 3 payments
  3. Senza $200 2 payments
  4. ORTHOVISC $153 6 payments
  5. Omnia $148 2 payments
  6. Gel-One Cross-linked Hyaluronate $127 3 payments
  7. RAYOS Rayos $124 2 payments
  8. RAYOS Rayos $124 2 payments
  9. RAYOS Rayos $124 2 payments
  10. BARRICAID ACD (ANNULAR CLOSURE DEVICE) $115 1 payment
  11. Other $1,070 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

196

Median for Internal Medicine: 777

Drug cost

$4,001

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 32 $3,049
Methylprednisolone Generic 48 $302
Celecoxib Generic 12 $215
Meloxicam Generic 38 $142
Pregabalin Generic 11 $130
Cyclobenzaprine Hcl Generic 30 $75
Meclizine Hcl Generic 11 $64
Tramadol Hcl Generic 14 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$77,743

Of which drugs: $31,450

Medicare patients

187

Average age 72

Services billed

12,537

111 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 34%
Diabetes 32%
Cancer 17%
Depression 16%
Osteoporosis 16%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 24 52 $21,342
Injection, methylprednisolone acetate, 1 mg J1010 Office 67 10,941 $1,121
Injection, methylprednisolone acetate, 40 mg J1030 Office 25 74 $342
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 74 340 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record